Veralox Therapeutics Announces FDA Orphan Drug Designation for VLX-1005
FREDERICK, Md.–(BUSINESS WIRE)–Veralox Therapeutics, a biotechnology company developing first-in-class small molecule therapeutics that treat the underlying pathologies of diseases with significant unmet medical needs, today announced that the U.S. Food … Read More